Lee Pharmaceuticals (LPHM) 0.0039 $LPHM 2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lee Pharmaceuticals (LPHM) 0.0039 $LPHM

2015 Investigation Report on China's Insulin Lispro Market 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
PR Newswire Europe - Thu Aug 06, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/963t94/investigation [http://www.researchandmarkets.com/research/963t94/investigation]) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" [http://www.researchandmarkets.com/research/963t94/investigation] report to their offering.
LLY: 79.20 (+0.25)

Research and Markets: Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
BusinessWire - Thu Aug 06, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8n6ks/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering.
LLY: 79.20 (+0.25)

Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
M2 - Thu Aug 06, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pbxrk/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development. There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million. For patients with type 1 diabetes mellitus, insulin is the only drug available. Besides, 30%-40% of type 2 diabetes will finally become insulin-dependent. Currently, the diabetic drug market at home and abroad both show rapid growth. Although international giants take up a large share, domestic enterprises are expected to break through in certain fields. The vast number of patients and demand for treatment will drive the diabetic drug market to expand. In recent years, insulin's share in the diabetic drug market has increasingly risen, 42% in the global market while nearly 40% in China. Insulin lispro is a fast-acting insulin analogue. Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, avoiding episodes of hypoglycemia. In the late 1990s, insulin lispro made by Eli Lilly and Company entered China. Later insulin lispro made by Gan & Lee Pharmaceuticals also came into the market. After entering China, insulin lispro develops fast with annual sales rising from less than CNY 7 million in 2005 to CNY 142 million in 2014 and CAGR during 2005-2014 reaching up to 40.1%. Currently, insulin lispro in the Chinese market mainly come from Eli Lilly and Company and Gan & Lee Pharmaceuticals. According to this market survey, Eli Lilly and Company has a larger market share of over 99% in 2014 by sales value. Key Topics Covered: 1Related Concepts of Insulin Lispro 2 Market Profile of Insulin Lispro in China 3 Survey on Sales Value of Insulin Lispro in China, 2010-2014 4 Survey on Sales Volume of Insulin Lispro in China, 2010-2014 5 Survey on Market Share of Major Manufacturers of Insulin Lispro in China, 2010-2014 6 Survey on Market Share of Dosage Forms of Insulin Lispro in China, 2010-2014 7 Reference Price of Insulin Lispro in Chinese Hospitals in 2014 8 Major Manufacturers of Insulin Lispro in Chinese Market, 2010-2014 9 Market Outlook of Insulin Lispro in China, 2014-2018 Companies Mentioned - Eli Lilly and Company - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/8p...estigation
LLY: 79.20 (+0.25)

The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 79.20 (+0.25)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading

Top 5 Most Recently Viewed Articles

3Srobotics Breaks Ground with North American Debut

Updated Category News Views 204

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025

Updated Category News Views 912

Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...

Continue Reading
Vivos Therapeutics to Share Q1 2025 Results and Updates Soon

Updated Category News Views 257

Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...

Continue Reading
Join XBP Global for the Annual Turkey Trot This Thanksgiving

Updated Category News Views 217

XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...

Continue Reading
Market Reaction to CEO Departure and Boot Barn's Strong Quarter

Updated Category News Views 317

Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...

Continue Reading